Comparative Pharmacology
Head-to-head clinical analysis: PANIXINE DISPERDOSE versus SPECTRACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANIXINE DISPERDOSE versus SPECTRACEF.
PANIXINE DISPERDOSE vs SPECTRACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Panixine is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Cefditoren, a third-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Cefpodoxime proxetil (Panixine Disperdose) is administered orally (PO) as a dispersible tablet. Typical adult dose: 200 mg PO every 12 hours for 10-14 days for community-acquired pneumonia; 100 mg PO every 12 hours for 5-7 days for acute exacerbation of chronic bronchitis; 200 mg PO single dose for uncomplicated gonorrhea.
400 mg orally twice daily for 10-14 days.
None Documented
None Documented
6-8 hours in healthy adults; prolonged in renal impairment (up to 20-30 hours in severe impairment).
Terminal elimination half-life: 2.5 hours (range 2.0-3.0 hours) in healthy adults; prolonged in renal impairment (up to 10 hours in severe impairment)
Renal excretion of unchanged drug accounts for 70-80% of elimination; biliary/fecal excretion accounts for 10-15%.
Renal: 88% as unchanged drug, Fecal: negligible, Biliary: minimal
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic